Evidence map›Paper›PMID 26058662›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.

Michael S Placzek, Genevieve C Van de Bittner, Hsiao-Ying Wey, Scott E Lukas, Jacob M Hooker

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Salvinorin A Does Not Affect Seizure Threshold in Mice.Molecules (Basel, Switzerland) · 2020
    Article
  4. Review
  5. A Survey of Molecular Imaging of Opioid Receptors.Molecules (Basel, Switzerland) · 2019
    Review
  6. Review
  7. Review
  8. Article
  9. PET Neurochemical Imaging Modes.Seminars in nuclear medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Michael S PlaczekDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Genevieve C Van de BittnerDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Hsiao-Ying WeyDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Scott E LukasDepartment of Psychiatry, McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Jacob M HookerDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Athinoula A. Martinos Center for Biomedical Imaging · USImaging Center · USMassachusetts General Hospital · US

Funding

ULTRAHIGH FIELD TECHNOLOGY FOR FUNCTIONAL IMAGINGP41RR014075 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BOAS, DAVID A · 1999 to 2011
$16.4M
Project 4P41EB015896 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2012 to 2018
$9.8M
Training In Drug Abuse and Brain ImagingT32DA015036 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI SCOTT E LUKAS · 2002 to 2026
$5.3M
Inveon: A Triple Modality Biomedical Imaging SystemS10RR029495 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BROWNELL, ANNA-LIISA · 2010 to 2010
$1.3M
Assessing Dynamic Opioid-Dopamine Interactions Using Simultaneous PET/MRIR00DA037928 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI WEY, HSIAO-YING · 2016 to 2018
$747k
MICROPET FOR ANIMAL STUDIESS10RR015728 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BROWNELL, ANNA-LIISA · 2001 to 2001
$500k
CYCLOTRON &RADIOCHEMISTRY: SUBSTANCE ABUSE, COCAINE, OPIOIDS10RR017208 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2004 to 2004
$500k
500 MHz NMR Spectrometer for Molecular Imaging ApplicationsS10RR023385 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2007 to 2007
$500k
Carbon-11 Radiopharmaceutical Production SystemS10RR026666 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BROWNELL, ANNA-LIISA · 2010 to 2010
$462k
Measure Mu-opioid Receptor Desensitization in vivoR21DA047133 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI WEY, HSIAO-YING · 2018 to 2019
$410k
Assessing Dynamic Opioid-Dopamine Interactions Using Simultaneous PET/MRIK99DA037928 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI WEY, HSIAO-YING · 2014 to 2015
$374k
NCRR NIH HHS P41RR14075NCRR NIH HHS S10RR015728NCRR NIH HHS S10RR017208NCRR NIH HHS S10 RR023385NCRR NIH HHS S10 RR026666NCRR NIH HHS S10RR026666NCRR NIH HHS S10 RR029495NIBIB NIH HHS P41EB015896NIDA NIH HHS K99DA037928NIDA NIH HHS R00 DA037928NIDA NIH HHS R21 DA047133NIDA NIH HHS T32 DA015036NIDA NIH HHS T32DA015036
6 · The paper itself

Abstract

Monitoring changes in opioid receptor binding with positron emission tomography (PET) could lead to a better understanding of tolerance and addiction because altered opioid receptor dynamics following agonist exposure has been linked to tolerance mechanisms. We have studied changes in kappa opioid receptor (KOR) binding availability in vivo with PET following kappa opioid agonist administration. Male Sprague-Dawley rats (n=31) were anesthetized and treated with the (KOR) agonist salvinorin A (0.01-1.8 mg/kg, i.v.) before administration of the KOR selective radiotracer [(11)C]GR103545. When salvinorin A was administered 1 min prior to injection of the radiotracer, [(11)C]GR103545 binding potential (BPND) was decreased in a dose-dependent manner, indicating receptor binding competition. In addition, the unique pharmacokinetics of salvinorin A (half-life ~8 min in non-human primates) allowed us to study the residual impact on KOR after the drug had eliminated from the brain. Salvinorin A was administered up to 5 h prior to [(11)C]GR103545, and the changes in BPND were compared with baseline, 2.5 h, 1 h, and 1 min pretreatment times. At lower doses (0.18 mg/kg and 0.32 mg/kg) we observed no prolonged effect on KOR binding but at 0.60 mg/kg salvinorin A induced a sustained decrease in KOR binding (BPND decreased by 40-49%) which persisted up to 2.5 h post administration, long after salvinorin A had been eliminated from the brain. These data point towards an agonist-induced adaptive response by KOR, the dynamics of which have not been previously studied in vivo with PET.

Indexed as

Analgesics, OpioidAnimalsBinding, CompetitiveBrainCarbon RadioisotopesDiterpenes, ClerodaneDose-Response Relationship, DrugMalePiperazinesPositron-Emission TomographyPyrrolidinesRadiopharmaceuticalsRats, Sprague-DawleyReceptors, Opioid, kappaTimeAnalgesics, OpioidCarbon RadioisotopesDiterpenes, ClerodaneGR 89696PiperazinesPyrrolidinesRadiopharmaceuticalsReceptors, Opioid, kappasalvinorin A

Identifiers

PMID26058662
PMCPMC4864638
OpenAlexW1508791536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.